Abstract
Introduction: Prostate cancer (Pc) is the most frequent neoplasia in men and the second cause of death in Brazil.
Objective: To analyze the interactions and biologicals responses of Pc oxidative stress and prostatespecific antigen (PSA), E-cadherin and MMP-13. Demonstrate whether the increase of the amount of the form of E-cadherin found in the plasma of Pc patients, correlates with decrease of the PSA.
Methods: Samples were obtained through peripheral venipuncture to analyse parameters of biomarkers pc as PSA, E-cadherin, MMP-13, Homocysteine, Folic acid, Vitamin B12, Testosterone T and free following the patients diagnosis, 3 and 6 months during their treatment to analyze the biological responses of Pc oxidative stress.
Results: The analysis was performed by using immunoenzymatic assay. Statistical data processed through Excel in Windows Vista and analyzed through the Shapiro-wilk Test, ANOVA, and Spearman Test. An increase in the concentration of E-cadherin (p = 0.02), as a decrease in concentration of PSA (p < 0.001), total testosterone (p < 0.001) and free testosterone (p = 0.02) was observed during the treatment period without significant alterations in the remaining markers for either of the periods.
Discussion: It was found that during treatment of men diagnosed with pc that there was an an increase in the concentration of plasmatic E-cadherin, which was negatively correlated with the concentrations of folic acid (-0,03 (0,87) rs (p). It was observed that the levels of hcy are positively correlated with concentrations of total testosterone and a negative correlation. Vitamins B12 remained within the parameters of normality during the entire study.
Conclusion: P.S.A levels were free and total testosterone levels decreased. In this way, monitoring the folic acid, E-cadherin dosages of patients during the treatment phases can effectively complement in the face of remission, since it would be a way of preventing abnormal cell replications, with a clinical view prudent so that the cell methylation cycle is not affected.
Keywords: Prostate cancer, metalloproteinase-13, E-cadherin, homocysteine, biomarkers, prostate-specific antigen.
Graphical Abstract
[http://dx.doi.org/10.1007/978-94-007-4186-7_9] [PMID: 22674073]
[http://dx.doi.org/10.2174/092986710791299966] [PMID: 20423306]
[http://dx.doi.org/10.1016/j.prnil.2016.05.002]
[http://dx.doi.org/10.1371/journal.pone.0022486] [PMID: 21853037]
[http://dx.doi.org/10.21800/S0009-67252014000100015]
[http://dx.doi.org/10.1002/ijc.20646] [PMID: 15499634]
[http://dx.doi.org/10.1590/S0104-42302006000100018] [PMID: 16622535]
[http://dx.doi.org/10.1038/modpathol.3880334] [PMID: 11353057]
[http://dx.doi.org/10.1016/j.intimp.2019.105708] [PMID: 31254956]
[http://dx.doi.org/10.1016/j.bbrc.2010.12.081] [PMID: 21184735]
[http://dx.doi.org/10.1016/j.bbamcr.2009.09.015] [PMID: 19800373]
[http://dx.doi.org/10.1590/S1676-24442010000100011]
[http://dx.doi.org/10.1210/jcem.83.2.4574] [PMID: 9467573]
[http://dx.doi.org/10.1016/j.clgc.2018.01.005] [http://dx.doi.org/10.1016/j.clgc.2018.01.005] [PMID: 29454638]
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0582] [PMID: 20852008]
[http://dx.doi.org/10.3748/wjg.v21.i4.1081]
[http://dx.doi.org/10.1016/j.bbrc.2003.10.044] [PMID: 14623320]
[http://dx.doi.org/10.5301/tj.5000237] [PMID: 25733385]